Skip to nav Skip to content
Julie  Hallanger Johnson

Julie Hallanger Johnson, MD

Program Lead, Endocrine Oncology
Program Leader, Endocrine Oncology Program
4.9 (213)

Specialty: Endocrinology

Program: Endocrine Oncology

  • Overview

    Cancer Focus:
    Adrenal Carcinoma, Adrenal Nodule/Mass, Pituitary Macroadenoma, Pituitary Microadenoma, Pituitary Neoplasm, Thyroid Cancer, Thyroid Nodule/Mass

    Dr. Julie Hallanger-Johnson is an Endocrinologist and Endocrine Program Leader in the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center. Dr. Hallanger-Johnson received her MD degree from the University of North Dakota School of Medicine. She completed an Internal Medicine Residency and Fellowship in Endocrinology and Metabolism at Mayo Clinic, Graduate School of Medicine in Rochester, MN. She then was a Clinical Assistant Professor of Medicine at the University of North Dakota, Grand Forks, ND. Dr. Hallanger-Johnson is a Clinical Educator Endocrinologist, with a particular interest in adrenal disease, including adrenal cancer, adrenal nodules, and pheochromocytoma/paraganglioma.  She also has extensive experience in the diagnosis and evaluation of thyroid disease and carries the Endocrine Certification in Neck Ultrasound (ECNU). Dr. Hallanger-Johnson is interested in the use of molecular markers and ultrasound information to guide decision-making in the evaluation of thyroid nodules, and the corresponding clinical outcomes research. She is interested in developing improved and more effective treatment options for patients with adrenal tumors. Dr. Hallanger-Johnson creates system improvements by developing timely and efficient pathways for patient care. 

    Education & Training

    Board Certification:

    • -


    • Mayo Graduate School of Medicine - Endocrinology and Metabolism


    • Mayo Graduate School of Medicine - Internal Medicine

    Medical School:

    • University of North Dakota School of Medicine and Health Sciences - MD
  • Participating Trials

    Clinical Trial 20873
    A Phase 1b, Open-Label Study of Relacorilant in Combination with Pembrolizumab for Patients with Adrenocortical Carcinoma with Excess Glucocorticoid Production
    Condition: Endocrine Oncology
    Intervention: Pembrolizumab (Keytruda); Relacorilant ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Nguyen OT, Turner K, Charles D, Sprow O, Perkins R, Hong YR, Islam JY, Khanna N, Alishahi Tabriz A, Hallanger-Johnson J, Bickel Young J, Moore CE. Implementing Digital Scribes to Reduce Electronic Health Record Documentation Burden Among Cancer Care Clinicians: A Mixed-Methods Pilot Study. JCO Clin Cancer Inform. 2023 Mar.7:e2200166. Pubmedid: 36972488.
    • Turner K, Stover AM, Tometich DB, Geiss C, Mason A, Nguyen OT, Hume E, McCormick R, Powell S, Hallanger-Johnson J, Patel KB, Kirtane KS, Jammigumpula N, Moore C, Perkins R, Rollison DE, Jim HSL, Oswald LB, Crowder S, Gonzalez BD, Robinson E, Tabriz AA, Islam JY, Gilbert SM. Oncology Providers' and Professionals' Experiences With Suicide Risk Screening Among Patients With Head and Neck Cancer: A Qualitative Study. JCO Oncol Pract. 2023 Jun.19(6):e892-e903. Pubmedid: 36395441. Pmcid: PMC10337750.
    • Padua TC, Marandino L, Raggi D, Hallanger-Johnson J, Kutikov A, Spiess PE, Necchi A. A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors. Clin Genitourin Cancer. 2023 Feb.21(1):1-7. Pubmedid: 36376169.
    • Hallanger Johnson J, El-Haddad G. Letter to the Editor From Hallanger Johnson and El-Haddad: "Yttrium-90 Selective Internal Radiation Therapy Plus Cryoablation for Recurrent Adrenocortical Carcinoma With Liver Metastases". J Endocr Soc. 2022 Oct.6(12):bvac154. Pubmedid: 36330293. Pmcid: PMC9620965.
    • Turner K, Bobonis Babilonia M, Naso C, Nguyen O, Gonzalez BD, Oswald LB, Robinson E, Elston Lafata J, Ferguson RJ, Alishahi Tabriz A, Patel K, Hallanger-Johnson J, Aldawoodi N, Hong YR, Jim HSL, Speiss PE. Health Care Providers' and Professionals' Experiences With Telehealth Oncology Implementation During the COVID-19 Pandemic: A Qualitative Study. J Med Internet Res. 2022 Jan.24(1):e29635. Pubmedid: 34907900. Pmcid: PMC8772877.
    • Strother M, Hallanger Johnson J, Kutikov A. A Point-of-Care Resource to Improve Care of Patients with Adrenal Mass: Eur Urol. 2022 Apr.81(4):434. Pubmedid: 35034801.
    • Seok K, Hallanger-Johnson J, Holmstrom B, Hembree T, Sharda E, Ramsakal A, Verma N. Literally Malignant Hypertension. SN Compr Clin Med. 2021 May.3:1960-1964.
    • Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021 Jan.31(1):36-49. Pubmedid: 32689909. Pmcid: PMC7864115.
    • Lu S, Dhillon J, Johnson JH, El-Haddad G. Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology. EJNMMI Res. 2021 Feb.11(1):17. Pubmedid: 33604708. Pmcid: PMC7892660.
    • Naffouje SA, Sabesan A, Hallanger-Johnson J, Kirtane K, Gonzalez RJ, Mullinax J. Adrenal biopsy, as a diagnostic method, is associated with decreased overall survival in patients with T1/T2 adrenocortical carcinoma: A propensity score-matched analysis. J Surg Oncol. 2021 Dec.124(8):1261-1271. Pubmedid: 34424540.
    • Keerty D, Das M, Hallanger-Johnson J, Haynes E. Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy. Cureus. 2020 Sep.12(9):e10632. Pubmedid: 33123445. Pmcid: PMC7584305.
    • Pereira MM, Williams VL, Hallanger-Johnson JE, Valderrabano P. Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations. Thyroid. 2020 Aug.30(8):1132-1140. Pubmedid: 32098591.
    • Valderrabano P, Hallanger-Johnson JE, Thapa R, Wang X, McIver B. Comparison of Postmarketing Findings vs the Initial Clinical Validation Findings of a Thyroid Nodule Gene Expression Classifier: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2019 Sep.145(9):783-792. Pubmedid: 31318389. Pmcid: PMC6647006.
    • Valderrabano P, Khazai L, Thompson ZJ, Otto KJ, Hallanger-Johnson JE, Chung CH, Centeno BA, McIver B. Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2018 Sep.144(9):788-795. Pubmedid: 30027226. Pmcid: PMC6233620.
    • Valderrabano P, Khazai L, Thompson ZJ, Sharpe SC, Tarasova VD, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Thyroid. 2018 Feb.28(2):210-219. Pubmedid: 29160163. Pmcid: PMC7869885.
    • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Chung CH, Centeno BA, McIver B. Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules. Head Neck. 2018 Aug.40(8):1812-1823. Pubmedid: 29624786. Pmcid: PMC7771319.
    • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach. Thyroid. 2017 Oct.27(10):1277-1284. Pubmedid: 28806881. Pmcid: PMC6112164.
    • Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, Hallanger-Johnson JE, Otto KJ, Rogers KD, Centeno B, McIver B. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer. 2017 Mar.24(3):127-136. Pubmedid: 28104680. Pmcid: PMC7771306.
    • Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, Hallanger-Johnson J, McIver B, Eberhardt NL. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther. 2013 May.20(5):267-275. Pubmedid: 23598436.
    • Khoo TK, Baker CH, Hallanger-Johnson J, Tom AM, Grant CS, Reading CC, Sebo TJ, Morris JC. Comparison of ultrasound-guided fine-needle aspiration biopsy with core-needle biopsy in the evaluation of thyroid nodules. Endocr Pract. 2008 May.14(4):426-431. Pubmedid: 18558594.
    • Hallanger Johnson JE, Kearns AE, Doran PM, Khoo TK, Wermers RA. Fluoride-related bone disease associated with habitual tea consumption. Mayo Clin Proc. 2007 Jun.82(6):719-724. Pubmedid: 17550752.
  • Patient Comments

    Overall Satisfaction


    213 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor